Check 35,000+ stocks against 26 valuation models and 37 quality factors

Cardinal Health Inc. (0HTG) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Cardinal Health Inc. $115, price $227, upside -49.2%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · GB · Home US

CH Some data Sep 24, 2026

Cardinal Health Inc.

0HTG · LSE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $115.26 · Strongly overvalued (−49.2%)

!Quality 58/100

!Mixed Growth (revenue 5y +7.8 %/yr)

!Thin margins · 0.6% net margin (TTM)

✓Negative equity (buybacks among others) · generates free cash flow

✓0.9% dividend yield · Well covered

!Mixed vs. peers (4/10)

!Narrow moat 19/100

!Evidence only medium, so the estimate is less certain

!Weak on dividend: 18 out of 100

26 models, one by oneBear $76.16 to bull $144.08 Growth analysisrevenue history, year by year Quality 58/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Cardinal Health Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $42.09 – $248.38 · fair‑value band $76.16 – $144.08 · the $226.69 price screens above the $115.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Cardinal Health in your weekly email

Every Wednesday you see whether Cardinal Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Stock analysis

Cardinal Health Inc. (0HTG) currently trades at $226.69, while our model-based Fair Value estimate is $115.26, 49.2% below the price, so the stock looks overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of $126.87 per share, and 0 of the 20 models we run sit above the $226.69 price.

Bear case: the Earnings-Based group reads lowest at $53.91, and 20 of the 20 models stay below the price. Evidence for this calculation is medium.

Scenario range: $76.16 (bear) to $144.08 (bull), the price of $226.69 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cardinal Health Inc. reported revenue of $223B in FY2025 versus $162B in FY2021, a compound +8.2%/yr. Reported net income was $1.6B in FY2025, compounding +26.4%/yr from FY2021.

Key figures

Market cap $54.9B · EPS (TTM) $−3.38 · Dividend yield 0.9% · Net margin 0.7% · Return on equity −171% · Return on assets (EBIT) 3.9% · Operating margin 1.4% · Revenue (TTM) $251B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 48% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at −49%, 0HTG screens richer than that median.

Fair Value models

Bear $76.16 Fair Value $115.26 Bull $144.08

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $74.87 $129.95 $218.55 78

Growth DCF $74.65 $125.90 $205.94 76

Owner Earnings $73.05 $126.87 $213.46 74

All 20 models by family

DCF Models

FCF DCF $74.87 $129.95 $218.55 78

Owner Earnings $73.05 $126.87 $213.46 74

5Y Revenue Exit $70.86 $123.97 $194.64 71

5Y EBITDA Exit $91.26 $164.82 $255.33 74

5Y P/E Exit $74.16 $130.59 $193.32 70

10Y Revenue Exit $69.10 $118.70 $191.63 65

10Y EBITDA Exit $84.56 $147.49 $239.93 67

10Y P/E Exit $73.60 $123.37 $190.58 63

Earnings-Based

Graham-Dodd $35.63 $148.97 $203.18 64

Lynch FV $37.74 $53.91 $70.09 61

PEG = 1.0 $37.74 $53.91 $70.09 57

EPV $54.37 $63.72 $71.79 74

Multiples

P/E Multiple $86.45 $115.26 $144.08 63

P/S Multiple $66.80 $89.07 $111.33 58

EV/EBIT $100.98 $136.25 $171.53 66

EV/EBITDA $110.14 $148.47 $186.80 67

EV/Revenue $70.68 $103.05 $135.42 53

Growth DCF

Growth DCF $74.65 $125.90 $205.94 76

Economic Profit

ROIC Compounder $54.37 $63.72 $71.79 72

Growth Earnings

Growth-Adj P/E $66.09 $94.41 $122.73 67

Open the full fair value analysis →

Notify me when 0HTG reaches fair value

Put 0HTG on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 58 · Market factors (momentum, volatility) 74

Profitability 44

Margins and returns on capital today

Quality Growth 35

Are margins and returns improving?

Cashflow 44

Earnings quality: real cash, not paper profit

Fin. Strength 62

Balance sheet, leverage, solvency risk

Investment 84

Disciplined investing over empire-building

Low Volatility 87

Calm price path (market factor)

Momentum 61

Price trend over the last 3–12 months (market factor)

52W Momentum 81

Distance to the 52-week high (market factor)

Net Issuance 100

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 65/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

−1.9%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.8%

Start year 2020 (pandemic). Over 10 years: +8.1% a year

Revenue growth 39 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+17.4%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+58.4%

Earnings growth per share plus dividend.

Earnings per share, growth per year+57.5%

Dividend (yield on the price)0.9%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.14.3% vs 6.0%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 1%

2025 sits 174% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+20.5%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+10.0%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +17.7% a year for the price and +7.5% for the forecasts.

Forecast 2026 (sales)+11.5%

Forecast 2027 (sales)+11.5%

Projected 2028 (sales)+10.3%

Projected 2029 (sales)+9.1%

Projected 2030 (sales)+7.9%

0HTG screens overvalued: fair value 49% below the price. Compare with McKesson Corporation →

Compare Cardinal Health Inc. with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 78 stocks

Beats the industry median on 4/10 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 58 · Above median

Fair Value upside −49.2% · Bottom 25%

Profitability

Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Return on assets 3.6% · Above median

Net margin (TTM) 0.6% · Below median

Operating margin (TTM) 1.4% · Below median

Growth and dividend

Revenue growth 11.0% · Top 25%

Dividend yield (TTM) 0.9% · Bottom 25%

Balance sheet

Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

P/S (TTM) 0.22× · Cheaper than median

P/FCF 29.7× · Priciest 25%

EV/EBITDA 14.1× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 45

FUTURE (revenue growth)55 · sector 13

PAST (return on equity)0 · sector 28

HEALTH (low debt)0 · sector 97

DIVIDEND (yield)18 · sector 58

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation MCK	$864.82	$822.74	−5%
Cencora, Inc COR	$309.78	$215.20	−31%
Henry Schein, Inc HSIC	$86.37	$76.77	−11%
Shanghai Pharmaceuticals Holding 601607	¥16.02	¥42.67	+166%
Sinopharm Group 1099	HK$14.88	HK$55.77	+275%
Galenica AG GALE	CHF 82.55	CHF 61.79	−25%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332	¥19.39	¥26.64	+37%
Jointown Pharmaceutical Group 600998	¥5.05	¥9.84	+95%
China National Medicines Corporation 600511	¥25.80	¥58.47	+127%
Hanmi Science Co 008930	52,800 KRW	21,059 KRW	−60%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cardinal Health Inc. · Fair Value
$115.26 −49%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/0HTG" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Cardinal Health Inc. · Fair Value</span><br><b style="font-size:20px">$115.26</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−49%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Cardinal Health Inc. Fair Value". https://www.fairvalue-calculator.com/stock/0HTG

Frequently asked questions

Is Cardinal Health Inc. (0HTG) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $115.26 versus a price of $226.69, about −49% upside (overvalued).

What is the fair value of 0HTG?

Our model-based fair value for Cardinal Health Inc. is $115.26 (as of Sep 24, 2026), built from audited fundamentals. The current price: $226.69.

What is the quality score of 0HTG?

Cardinal Health Inc. has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Cardinal Health Inc. (0HTG)?

Our model-based price target is the fair value of $115.26 (as of Sep 24, 2026) from 20 valuation models. Cautious scenario $76.16, optimistic scenario $144.08. It is a calculation from audited fundamentals, not an analyst target.

What is the Cardinal Health Inc. stock forecast for 2026?

Our models put fair value at $115.26, about −49% upside versus a price of $226.69 (overvalued). Cautious scenario $76.16, optimistic scenario $144.08. The calculation is refreshed regularly with new filings.

What is the revenue of Cardinal Health Inc. (0HTG)?

Cardinal Health Inc. reported trailing-twelve-month revenue of about $251B (latest available figure, as of Sep 24, 2026).

Does Cardinal Health Inc. pay a dividend?

Cardinal Health Inc. currently shows a dividend yield of about 0.90% relative to its recent price (as of Sep 24, 2026).

What growth is priced into Cardinal Health Inc. (0HTG)?

For today's price to be fair in a discounted-cash-flow model, Cardinal Health Inc. would have to grow free cash flow by +20.5 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.8 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 0HTG use?

Our models discount Cardinal Health Inc. at 9.0 %: a base by market capitalisation (unknown), damped by beta 0.49, country premium for United Kingdom. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cardinal Health Inc. that is +20.5 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.

How much growth has Cardinal Health Inc. (0HTG) delivered so far?

Over the past 5 years revenue at Cardinal Health Inc. grew +7.8 % a year. The price currently implies +20.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Cardinal Health Inc. (0HTG) growing?

The median revenue growth in the sector is +7.1 % a year. That is the yardstick for the growth priced into Cardinal Health Inc. (+20.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Cardinal Health Inc. (0HTG)?

The free-cash-flow yield on the price is 2.55 %: that much free cash flow Cardinal Health Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Cardinal Health Inc. (0HTG)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cardinal Health Inc. it is $115.26 per share (as of Sep 24, 2026), against a price of $226.69. It is the blended result of 20 valuation models (cash flow, earnings, asset, dividend).

Is Cardinal Health Inc. stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 0HTG trades above its calculated fair value: price $226.69, fair value $115.26, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0HTG?

No. The price is what the market pays today ($226.69); the fair value is what the company's own numbers justify ($115.26). For Cardinal Health Inc. the two are $111.43 per share apart. That gap is exactly why we show both numbers side by side.

How much is Cardinal Health Inc. worth?

The market values Cardinal Health Inc. at about $54.9B (market capitalisation, as of Sep 24, 2026). Per share that is $226.69; our models calculate a fair value of $115.26 per share.

What do the bullish and bearish scenarios say about 0HTG?

Our models span a range for Cardinal Health Inc.: cautious scenario $76.16, base $115.26, optimistic $144.08 per share (as of Sep 24, 2026, price $226.69). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Cardinal Health Inc. (0HTG)?

Balance-sheet figures for Cardinal Health Inc. (as of Sep 24, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 58/100, which measures business quality independently of the share price.

How far is 0HTG from its 52-week high?

Cardinal Health Inc. trades at $226.69, about 9% below its 52-week high of $248.38 and 48% above the low of $153.63 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $115.26 is for.

Which stocks are comparable to Cardinal Health Inc.?

From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Henry Schein, Inc, Shanghai Pharmaceuticals Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Cardinal Health Inc. stock attractive at the current price?

The data as of Sep 24, 2026: price $226.69, calculated fair value $115.26 (−49%), Quality Score 58/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0HTG calculated?

We run Cardinal Health Inc. through 20 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $115.26, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Cardinal Health Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Cardinal Health Inc. (0HTG)?

The closing price on Oct 2, 2026 was $226.69. Our model-based fair value is $115.26, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Cardinal Health Inc. right now?

The price sits above even our optimistic bull case ($144.08). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($76.16 to $144.08) leaves room in how you read the outcome.

Where does the earnings growth of Cardinal Health Inc. (0HTG) come from?

Earnings per share at Cardinal Health Inc. grew −0.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +12.1 %, EBIT margin −10.3 %, tax rate +1.1 %, residual (interest, one-offs) −2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Cardinal Health Inc.

How large is the market capitalisation of Cardinal Health Inc. (0HTG)?

The market capitalisation of Cardinal Health Inc. is $54.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Cardinal Health Inc. (0HTG)?

Earnings per share at Cardinal Health Inc. are $−3.38. Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Cardinal Health Inc. (0HTG)?

The dividend yield of Cardinal Health Inc. is 0.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Cardinal Health Inc. (0HTG)?

The net margin of Cardinal Health Inc. is 0.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Cardinal Health Inc. (0HTG)?

The return on equity (ROE) of Cardinal Health Inc. is −171% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Cardinal Health Inc. (0HTG)?

On an EBIT basis the return on assets of Cardinal Health Inc. is 3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Cardinal Health Inc. (0HTG)?

The operating margin of Cardinal Health Inc. is 1.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Cardinal Health Inc. (0HTG)?

Revenue at Cardinal Health Inc. is growing +11.0% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Cardinal Health Inc. (0HTG)?

Earnings per share at Cardinal Health Inc. are growing −19.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Cardinal Health Inc. (0HTG) carry?

The net debt of Cardinal Health Inc. is $5.5B (fiscal year 2025, ≈ 3.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Cardinal Health Inc. in the live analysis

One click puts Cardinal Health Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.